Fresh analysis indicates that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain shed pounds far faster than those who halt conventional lifestyle regimens.
Research printed in a major health publication points out that while overweight people can lose a large proportion of their body weight while on the medication, the weight returns at an average rate of 0.8 kg per month once they quit.
"Individuals buying such medications should be informed of the risk of fast rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb.
This pace of regain means a return to pre-treatment mass within about one and a half years.
Comparing Therapies
The study, which examined dozens of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
Researchers note that people who shed pounds through lifestyle changes alone generally have a slower weight regain—around 100 grams monthly—once they finish.
Explaining the Quick Rebound
Doctors propose the mode of action of the drugs explains the heightened rebound.
GLP-1 drugs mimic a natural hormone called GLP-1, which controls feelings of fullness.
"Long-term administration of GLP-1 levels far above than normal might result in the system to generate a reduced amount of its endogenous hormone, and may also lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Discontinuation of this medication leads to appetite is no longer kept in check, making overeating a significant risk."
An Ongoing Condition?
Health authorities advise the injections for people with weight-linked health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, considering the likelihood of weight regain, the therapy might need to be life-long.
This view is supported by pharmaceutical companies, who note that the results "emphasize the long-term character of excess weight," comparing it to managing conditions like hypertension.
User Testimonies
People who have stopped the jabs describe a intense return of cravings.
"I experienced something that goes on and you're instantly extremely hungry," described one woman.
This difficulty is worsened if users have not developed lasting dietary or behavioural changes during treatment.
Significant Use
Figures suggest that a significant number of adults in the UK have tried these injections in the last 12 months, with interest continuing to grow.
- Use is higher among females than men.
- The 40s and 50s age group shows the highest usage rates.
- A large proportion access the medications through private prescriptions rather than the NHS.
In conclusion, researchers emphasize that while the jabs are potent tools for shedding pounds, they are not a standalone solution and long-term success relies on combined behavioural support.
